At a glance
ClinicalIndex Comparison RecordN/ACompleted· 575 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis Patients in a Real-world Clinical Setting. PROOF-Registry New and Extended Belgium -Luxembourg
In Brief
An observational study for Idiopathic Pulmonary Fibrosis. Completed, enrolled 575 participants across 9 sites in 2 countries.
Detailed Summary
A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesBelgium, Luxembourg
CollaboratorsBoehringer Ingelheim, Roche Farma, S.A
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedNov 2018
Primary CompletionNov 2021
Study CompletionJan 2022
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartJan 9, 2018
Primary CompletionNov 1, 2021
Study CompletionJan 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.7 years ago